L-citrulline takes a different route
It works by activating three hormone pathways involved in appetite regulation and energy balance, GLP-1, GIP, and glucagon, which is why its dosing approach is structured differently than single-pathway therapies
Because DSIP research is largely historical and not industrially funded, it lacks standardized research protocols, making comparison across studies difficult
Tirzepatide adds GIP activation, which slightly alters the profile
This is likely due to its dual-action mechanism targeting two hormone pathways (GIP and GLP-1) vs Wegovys sole focus on GLP-1
It should not replace first-line, evidence-based treatment for any GI condition